FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018560760> ?p ?o ?g. }

• W2018560760 endingPage "2012" @default.
• W2018560760 startingPage "2002" @default.
• W2018560760 abstract "Abstract Interleukin (IL)‐2 has been approved for treatment of metastatic renal cancer and malignant melanoma. However, its unfavorable pharmacologic properties, severe side effects and the negative role of IL‐2 in maintaining T regulatory cells are severe drawbacks. It has been shown that immunocomplexes of IL‐2 and certain anti‐IL‐2 mAbs possess selective and high stimulatory activity in vivo. Here, we show that IL‐2/S4B6 mAb immunocomplexes expand not only CD122 high subsets and newly activated CD8 + T cells but also natural killer T cells and γδ T cells. Further, we demonstrate that natural killer (NK) cells expanded by IL‐2/S4B6 mAb immunocomplexes in vivo have high cytolytic activity, which can be further increased by coadministration of IL‐12. We also demonstrate that IL‐2/S4B6 mAb immunocomplexes possess noticeable antitumor activity in two syngeneic mouse tumor models, namely BCL1 leukemia and B16F10 melanoma, but only if administered early in tumor progression. To effectively treat established tumors, we administered the tumor‐bearing mice first with N ‐(2‐hydroxypropyl)methacrylamide copolymer‐bound doxorubicin conjugate, and subsequently with IL‐2/S4B6 mAb immunocomplexes alone or with IL‐12 to induce an efficient antitumor immune response. Importantly, we show that the conjugate has significantly lower immunosuppressive activity than free doxorubicin when using dosage with comparable antitumor activity, thus eliminating the majority of tumor cells while leaving the immune system mostly unimpaired for stimulation with IL‐2/S4B6 mAb immunocomplexes. Indeed, we demonstrate that the conjugate and IL‐2/S4B6 mAb immunocomplexes together have synergistic antitumor activity." @default.
• W2018560760 created "2016-06-24" @default.
• W2018560760 creator A5001240494 @default.
• W2018560760 creator A5007204536 @default.
• W2018560760 creator A5010623487 @default.
• W2018560760 creator A5017762135 @default.
• W2018560760 creator A5040270800 @default.
• W2018560760 creator A5060179690 @default.
• W2018560760 creator A5088745217 @default.
• W2018560760 date "2011-04-13" @default.
• W2018560760 modified "2023-10-18" @default.
• W2018560760 title "Antitumor activity of IL-2/anti-IL-2 mAb immunocomplexes exerts synergism with that of<i>N</i>-(2-hydroxypropyl)methacrylamide copolymer-bound doxorubicin conjugate due to its low immunosuppressive activity" @default.
• W2018560760 cites W122937650 @default.
• W2018560760 cites W1576342294 @default.
• W2018560760 cites W1894367943 @default.
• W2018560760 cites W1947939079 @default.
• W2018560760 cites W1967884480 @default.
• W2018560760 cites W1979867927 @default.
• W2018560760 cites W1988773196 @default.
• W2018560760 cites W1993897063 @default.
• W2018560760 cites W1993898431 @default.
• W2018560760 cites W1996642272 @default.
• W2018560760 cites W1997919830 @default.
• W2018560760 cites W2000814028 @default.
• W2018560760 cites W2005155327 @default.
• W2018560760 cites W2008865476 @default.
• W2018560760 cites W2013952994 @default.
• W2018560760 cites W2016612145 @default.
• W2018560760 cites W2019863692 @default.
• W2018560760 cites W2026986549 @default.
• W2018560760 cites W2036772644 @default.
• W2018560760 cites W2044030495 @default.
• W2018560760 cites W2049195346 @default.
• W2018560760 cites W2055522356 @default.
• W2018560760 cites W2063312254 @default.
• W2018560760 cites W2063985611 @default.
• W2018560760 cites W2090790300 @default.
• W2018560760 cites W2093424661 @default.
• W2018560760 cites W2095138364 @default.
• W2018560760 cites W2104049583 @default.
• W2018560760 cites W2109427953 @default.
• W2018560760 cites W2118326757 @default.
• W2018560760 cites W2141285069 @default.
• W2018560760 cites W2156067155 @default.
• W2018560760 cites W2167985290 @default.
• W2018560760 doi "https://doi.org/10.1002/ijc.25859" @default.
• W2018560760 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21165950" @default.
• W2018560760 hasPublicationYear "2011" @default.
• W2018560760 type Work @default.
• W2018560760 sameAs 2018560760 @default.
• W2018560760 citedByCount "8" @default.
• W2018560760 countsByYear W20185607602012 @default.
• W2018560760 countsByYear W20185607602013 @default.
• W2018560760 countsByYear W20185607602014 @default.
• W2018560760 countsByYear W20185607602015 @default.
• W2018560760 countsByYear W20185607602019 @default.
• W2018560760 countsByYear W20185607602023 @default.
• W2018560760 crossrefType "journal-article" @default.
• W2018560760 hasAuthorship W2018560760A5001240494 @default.
• W2018560760 hasAuthorship W2018560760A5007204536 @default.
• W2018560760 hasAuthorship W2018560760A5010623487 @default.
• W2018560760 hasAuthorship W2018560760A5017762135 @default.
• W2018560760 hasAuthorship W2018560760A5040270800 @default.
• W2018560760 hasAuthorship W2018560760A5060179690 @default.
• W2018560760 hasAuthorship W2018560760A5088745217 @default.
• W2018560760 hasBestOaLocation W20185607601 @default.
• W2018560760 hasConcept C126322002 @default.
• W2018560760 hasConcept C150903083 @default.
• W2018560760 hasConcept C159654299 @default.
• W2018560760 hasConcept C203014093 @default.
• W2018560760 hasConcept C207001950 @default.
• W2018560760 hasConcept C2776694085 @default.
• W2018560760 hasConcept C2777658100 @default.
• W2018560760 hasConcept C2781303535 @default.
• W2018560760 hasConcept C502942594 @default.
• W2018560760 hasConcept C542903549 @default.
• W2018560760 hasConcept C71924100 @default.
• W2018560760 hasConcept C86803240 @default.
• W2018560760 hasConcept C8891405 @default.
• W2018560760 hasConcept C98274493 @default.
• W2018560760 hasConceptScore W2018560760C126322002 @default.
• W2018560760 hasConceptScore W2018560760C150903083 @default.
• W2018560760 hasConceptScore W2018560760C159654299 @default.
• W2018560760 hasConceptScore W2018560760C203014093 @default.
• W2018560760 hasConceptScore W2018560760C207001950 @default.
• W2018560760 hasConceptScore W2018560760C2776694085 @default.
• W2018560760 hasConceptScore W2018560760C2777658100 @default.
• W2018560760 hasConceptScore W2018560760C2781303535 @default.
• W2018560760 hasConceptScore W2018560760C502942594 @default.
• W2018560760 hasConceptScore W2018560760C542903549 @default.
• W2018560760 hasConceptScore W2018560760C71924100 @default.
• W2018560760 hasConceptScore W2018560760C86803240 @default.
• W2018560760 hasConceptScore W2018560760C8891405 @default.
• W2018560760 hasConceptScore W2018560760C98274493 @default.
• W2018560760 hasIssue "8" @default.
• W2018560760 hasLocation W20185607601 @default.
• W2018560760 hasLocation W20185607602 @default.
• W2018560760 hasOpenAccess W2018560760 @default.

• next